Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study
<p>Abstract</p> <p>Background</p> <p>Indacaterol is a novel once-daily ultra long-acting β<sub>2</sub>-agonist for the treatment of chronic obstructive pulmonary disease. It is known that β<sub>2</sub>-agonists, like other adrenergic compounds, c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-05-01
|
| Series: | BMC Pulmonary Medicine |
| Online Access: | http://www.biomedcentral.com/1471-2466/11/31 |